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ABSTRACT
Objective: To compare the cost-effectiveness of pegaptanib
and usual care within three distinct cohorts of subfoveal
neovascular age-related macular degeneration (NV-AMD)
patients, that is, those with early, moderate, and late disease,
using a comprehensive economic model.
Methods: A Markov framework was used to model lifetime
movement of a subfoveal NV-AMD cohort through health
states based on visual acuity. The model takes a US payer
perspective of patients over the age of 65 years. Clinical
efﬁcacy was based on published results for the 0.3 mg pegap-
tanib and usual care groups. Expert interviews were con-
ducted to determine adverse event treatment patterns and
vision rehabilitation resource use. Incidence and costs of
comorbidities such as depression and fractures associated
with the effects of declining visual acuity were based on our
previously published analysis of Medicare data. Transition
probabilities were derived from published clinical trial data
for each 3-month cycle. Utilities were derived from published
sources. Three runs of the model were conducted with
cohorts of newly diagnosed patients. Patients were classiﬁed
as having early, moderate, or late NV-AMD deﬁned as visual
acuity in the better-seeing eye of 20/40 to more than 20/80,
20/80 to more than 20/200, and 20/200 to more than 20/400,
respectively. Costs and outcomes were discounted 3.0% per
annum.
Results: Incremental costs per vision-year gained and per
quality-adjusted life-year (QALY) gained for early NV-AMD
patients were approximately one-third those of patients with
late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381,
respectively). On average, patients treated early with either
pegaptanib or usual care incurred lower lifetime total direct
costs than those treated later. Sensitivity analysis showed that
base-case incremental costs per QALY gained for pegaptanib
versus usual care were relatively robust.
Conclusions: For patients with subfoveal NV-AMD, treat-
ment with pegaptanib should be started as early as possible to
maximize the clinical and economic beneﬁts.
Keywords: age-related macular degeneration, cost-effective-
ness, Markov model, pegaptanib.
Introduction
Neovascular age-related macular degeneration (NV-
AMD) is a progressive, rapidly developing disease
leading to central vision loss and eventually to blind-
ness. Population-based studies across developed coun-
tries have estimated the prevalence rate of advanced
age-related macular degeneration (AMD), either AMD
with geographic atrophy or NV-AMD, to be between
1.7 and 1.9 per 100 individuals [1]. By the year 2020,
almost 3 million individuals will suffer from NV-AMD
or geographic atrophy in the United States alone [2].
The resulting visual impairment affects patient quality
of life as much as arthritis, asthma, diabetes, and
stroke [3]. The economic burden of AMD is high
because people with impaired vision may experience
an increased risk of falls and fractures [4–6], depres-
sion [7,8], and the need for daily support services or
nursing home care [9]. In the United States, the yearly
economic loss to the gross domestic product from
NV-AMD-related sequelae has been estimated to be
$2.866 billion for those aged 65 years and older and
$2.530 billion for individuals younger than 65 years
[10].
The functional abilities of AMD patients and the
cost-effectiveness of AMD treatments have been found
to vary according to visual acuity level. For example,
AMD patients with early disease (visual acuity better
than 20/80) reported a signiﬁcantly lower quality of
life than those without AMD, and consistent trends
toward worse quality of life were demonstrated as
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visual acuity progressed toward blindness [11]. Using
the time trade-off method of utility analysis, those with
clinically severe AMD were found to have, on average,
a signiﬁcantly worse self-perceived health-related
quality of life than those with milder AMD [12]. Sever-
ity of AMD also has been shown to be associated with
lower scores on the Activities of Daily Vision Scale,
particularly for near vision and driving [13]. A cost-
effectiveness assessment [14] considered the treatment
beneﬁt of photodynamic therapy with verteporﬁn
(PDT) for NV-AMD patients. PDT therapy, which is
indicated only for predominantly classic lesions,
involves injection of verteporﬁn through a vein in the
hand or arm; the drug circulates through the body and
attaches to abnormal vessels beneath the macula;
verteporﬁn is activated by a laser shone into the back
of the eye leading to closure of abnormal blood vessels
and stoppage of leaking of ﬂuid and blood beneath the
retina. Using two baseline vision thresholds, 20/40 and
20/200, the authors found treatment to be less cost-
effective in NV-AMD patients with lower visual
acuities; PDT for a patient with 20/40 vision in the
better-seeing eye would cost an insurer $86,721 to
obtain one quality-adjusted life-year (QALY) versus
$173,984 per QALY for a patient with 20/200 vision
in the better-seeing eye [14].
In the current health-care environment, it is impor-
tant to allocate limited resources to their most efﬁ-
cient use to maximize health and cost beneﬁts. This
approach includes not only the selection of but also
the timing of therapeutic interventions. This report
addresses the use and timing of pegaptanib sodium
(Macugen) in the treatment of NV-AMD. By way of
review, pegaptanib is a selective inhibitor of the 165
isoform of vascular endothelial growth factor (VEGF)
and is indicated for all subtypes of NV-AMD [15]. It
has been suggested that early treatment of NV-AMD
with pegaptanib may limit choroidal neovasculariza-
tion (CNV)-induced damage to photoreceptors and/or
the retinal pigment epithelium and so be associated
with better vision results. An exploratory analysis of
data from the VEGF Inhibition Study in Ocular
Neovascularization (V.I.S.I.O.N.) [16] trial found that
early detection and treatment with pegaptanib in sub-
jects with early NV-AMD resulted in superior vision
outcomes. For example, in patients with early disease
deﬁned as occult with no classic CNV, absence of lipid,
and better baseline visual acuity in the fellow eye, the
week-54 responder rate was 80% (24/30) among those
treated with 0.3 mg pegaptanib versus 57% (20/35) in
the usual care group (P = 0.05). Thus, early treatment
may lead to reduced resource use as patient function-
ality is maintained, along with measurable preserva-
tion in patient quality of life.
In order to better understand the implications of
these clinical studies, we developed a comprehensive
economic model comparing the cost-effectiveness of
pegaptanib and usual care within three distinct cohorts
of NV-AMD patients, that is, those with early, moder-
ate, and late disease.
Materials and Methods
Model Scope
A Markov framework was used to model the lifetime
movement of an NV-AMD cohort through ﬁve health
states based on visual acuity in the better-seeing eye
(Fig. 1). This approach was ﬁrst developed in ophthal-
mology to assess the treatment of diabetic eye disease
[17]. Visual acuity in the better-seeing eye was used
because previous studies have shown that costs [18]
and quality of life [19] are highly correlated with visual
acuity in that eye. The model’s structure was validated
through interviews with clinical experts and accounted
for different time horizons (cycle time: 3 months; base
Figure 1 Markov model structure. Patients may transition to the death
state from any state in the model. The 20/200 states represent legal
blindness.
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case: lifetime), distributions of patient age and sex,
lesion subtypes, and starting visual acuity levels. The
model takes a US payer perspective and does not
consider either indirect costs or patient out-of-pocket
expenses. The perspective was that of a typical cost
utility analysis where costs to the payer are assessed
against utility beneﬁts to the patient. Because
NV-AMD primarily affects the elderly [20–23], this
analysis is restricted to those age 65 years and older.
Comparators were pegaptanib and usual care based on
the results of a 2-year clinical study, the V.I.S.I.O.N.
trial [15,24,25].
V.I.S.I.O.N.Trial
Two pivotal phase 2/3 multicenter, randomized,
double-masked trials [15,24,25] in patients with all
subtypes of NV-AMD were performed. Intravitreal
pegaptanib (0.3 mg, 1 mg, or 3 mg) or sham injection
was administered every 6 weeks for 54 weeks. At week
54, those assigned to pegaptanib were rerandomized to
continue or discontinue treatment for 48 additional
weeks (8 injections); patients assigned to usual care
(sham) in year 1 were rerandomized to continue or
discontinue usual care or to receive one of the three
pegaptanib doses. At the time of the V.I.S.I.O.N. trial,
PDT was the only treatment indicated for patients with
NV-AMD, and the trial design allowed the use of PDT
in both the experimental and the usual care arms at the
discretion of the physician. In all, 1186 subjects were
included in year-1 efﬁcacy analyses. In the 0.3 mg
(approved dose) group, 70% of subjects lost <3 lines of
visual acuity (were responders) compared to 55% of
those receiving usual care (P < 0.001); severe vision
loss (6 lines) was half as frequent in the pegaptanib
compared to usual care groups occurring in 10% and
22% of subjects, respectively (P < 0.001). In year 2,
1053 patients were rerandomized, and 941 were evalu-
ated at week 102. Ongoing visual beneﬁt was seen in
subjects who received pegaptanib continuously com-
pared to 2 years of usual care or pegaptanib cessation.
Loss of <3 lines from baseline between weeks 54 and
102 was seen in 7% of subjects who continued pegap-
tanib, compared to 14% of those who either discon-
tinued pegaptanib or remained on usual care. Over
2 years, pegaptanib was well tolerated, and most
ocular adverse events were transient, mild to moderate
in intensity, and related to the injection. Endoph-
thalmitis occurred at a rate of 0.16% per injection in
year 1, and 9/12 subjects who developed endoph-
thalmitis remained in the trial. No case of endoph-
thalmitis was reported in year 2.
Input Parameters
Patient parameters. Distributions of patients by age
and sex groupings were based on the US population
[26]. Patient ages were grouped as 65 to 74 years and
more than 74 years; the model scenario reported
herein included patients aged 65 years or older.
The annual incidence of advanced AMD, deﬁned as
either NV-AMD or AMD with geographic atrophy, by
age and sex group was estimated based on the 10-
year incidence data [27]. The model considered only
patients with subfoveal NV-AMD because pegaptanib
and PDT have prescribing patterns that overlap in
these patients. To speciﬁcally model a population with
subfoveal NV-AMD, the number of patients in each
age and sex group was derived by multiplying the age-
and sex-speciﬁc annual incidence rate of advanced
AMD by 69.47% (NV-AMD) [2]. We then narrowed
the NV-AMD population by extracting only those with
subfoveal disease or 78.50% of the NV-AMD subjects
[28]. The model included patients with all subtypes of
subfoveal NV-AMD: predominantly classic CNV (area
of entire lesion was 50% classic; 20.00% of patients),
minimally classic CNV (area of classic component was
<50% of the entire lesion; 7.00%), and occult with no
classic CNV (73.00%) [28].
Three runs of the model were conducted with
cohorts of newly diagnosed patients. Patients were
classiﬁed as having early, moderate, or late subfoveal
NV-AMD deﬁned as visual acuity in the better-seeing
eye of 20/40 to more than 20/80, 20/80 to more than
20/200, and 20/200 to more than 20/400, respectively.
The initial distribution of patients within these visual
acuity ranges was obtained from the baseline visual
acuity distribution of all patients in the V.I.S.I.O.N.
trial (early, 36.05%; moderate, 46.05%; late, 17.06%)
[15]. All patients were assumed to have bilateral
disease.
Age- and sex-speciﬁc all-cause mortality rates were
derived from US Vital Statistics Reports [29]. Speciﬁ-
cally, all-cause mortality by 10-year age groups was
obtained. Mortality rates for each patient age were
then projected by ﬁtting curves to these data. An analy-
sis of Medicare claims data showed that patients who
are blind (visual acuity: 20/200) have a relative risk of
death of 1.5 compared to patients who are not blind
[30]. In the model, mortality rates were derived by
applying a relative risk of 1.5 to the age- and sex-
speciﬁc mortality rates for the US population to the
20/200 to more than 20/400 visual acuity state. For all
model states, mortality rates increased as patients aged
in the model.
Clinical efﬁcacy and safety parameters. Clinical efﬁ-
cacy measured by visual acuity was based on
V.I.S.I.O.N. trial [15,24] results for the 0.3 mg pegap-
tanib group and for those receiving usual care. Three-
month transition probabilities for the ﬁrst and second
years of treatment were estimated using the ﬁrst-
and second-year cumulative clinical probabilities for
pegaptanib or usual care in terms of loss or gain in
lines of visual acuity (Table 1). A decrement of three
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lines represented a transition to the next level of visual
acuity, and a loss of six lines brought a patient down
two levels of visual acuity. The converse logic applied
to lines of visual acuity gained. For instance, if a
subject at baseline was within the visual acuity state
ranging from 20/80 to 20/200 and on treatment the
subject’s vision improved by three lines, this subject
transitioned to the 20/40 to 20/80 visual acuity state.
Clinical experts were interviewed to identify poten-
tially clinically signiﬁcant adverse events for the model.
Six experts reviewed the list of adverse events re-
ported during the V.I.S.I.O.N. trial [15,25] and iden-
tiﬁed those events considered to be most important
clinically and most likely to substantially impact costs.
Three adverse events were included in the model, and
their annual rates of occurrence were obtained from
the V.I.S.I.O.N. trial [15,25]: endophthalmitis, 1.35%;
traumatic injury to lens, 0.56%; and retinal detach-
ment, 0.67%. The model assumed that adverse event
rates were independent of lesion subtype and visual
acuity states.
Utilities. Utility values ranged from 0.0 to 1.0, where
1.0 represented perfect health and 0.0 represented
death. Like previous AMD models [14,31], utility
values for the visual acuity states were obtained from a
study by Brown et al. [32] in which utilities for AMD
patients were measured empirically using time trade-
off and standard gamble methods. The visual acuity
ranges used by Brown et al. [32] were mapped as
closely as possible to the thresholds measured in clini-
cal trials (Table 2).
Resource Use and Cost Parameters
The average number of outpatient appointments for
patients treated with pegaptanib was assumed to be
equal to the average number of pegaptanib treatments
per year. Thus, patients were assumed to have 8.4 and
6.9 outpatient appointments and drug administrations
in years 1 and 2, respectively. The average unit cost of
an outpatient appointment, pegaptanib procedure, and
pegaptanib were estimated at $65.18, $202.75, and
$1054.70, respectively [33,34]. We also assumed that
pegaptanib treatment did not require any additional
rounds of ﬂuorescein angiography or optical coherence
tomography, because those modalities are speciﬁcally
not part of the recommended indications for pegap-
tanib administration. The model assumed that patients
in the usual care arm received either PDT or no treat-
ment. The cost of PDT and an administration of PDT
within 1 year was estimated at $1341.90 and $323.64.
Percentages of patients receiving PDT and average
number of treatments in years 1 and 2 were based on
ﬁndings of the V.I.S.I.O.N. trial [15,24] (Table 3).
Total annual costs of primary and concomitant thera-
pies are presented in Table 3. Drug and procedure
costs were based on unit costs from US published
sources, including Medicare Part B Drugs Average
Sales Prices [33] and the Resource-Based Relative
Value Scale (RBRVS) [34] based on their respective
Current Procedural Terminology (CPT) codes. The
model assumed as a default that treatment ceased if
visual acuity dropped below 20/400.
To estimate the economic impact of these
treatment-related adverse events (e.g., endophthalmi-
tis, traumatic injury to lens, and retinal detachment),
interviews with six clinical experts were performed.
Speciﬁcally, the clinical experts estimated the percent-
age of patients who would be treated for each adverse
event and speciﬁed treatment patterns for those
patients. Unit costs for resources were obtained from
the RBRVS based on their respective CPT codes
(Table 4) [34]. Modeled costs for treating adverse
events accounted for PDT-related adverse events
among patients who received PDT in addition to
pegaptanib or usual care. Long-term clinical conse-
quences such as potential reduction in vision were
assumed to be considered in the clinical efﬁcacy as seen
in the trial.
Patients with low vision, in particular those with
AMD, suffer from numerous comorbidities and fre-
quently require assistance with activities of daily
living. A recent analysis of US Medicare data demon-
strated that people with impaired vision are at greater
risk than the general population of depression, injuries
such as fractures, and the need for skilled nursing
facility or nursing home care [18]. The model allowed
patients with varying degrees of visual acuity to use
resources at varying rates and to incur varying costs.
Table 1 Three-month transition probabilities by treatment
year, all lesion subtypes
Pegaptanib (%) Usual care (%)
Year 1 Year 2 Year 1 Year 2
Gain of 3 lines or more 1.57 0.93 0.51 0.43
Loss of 3–6 lines 5.55 2.11 6.21 1.62
Loss of 6 lines or more 2.47 0.82 6.01 1.07
No progression (gain or loss
of <3 lines)
90.42 96.14 87.26 96.88
Table 2 Utilities for patients with age-related macular degen-
eration using visual acuity in the better-seeing eye
Model visual acuity range
Visual acuity
range in
Brown et al. [32]
Utility in Brown
et al. [32] and
model*
Unilateral NV-AMD NA 0.89
>20/40 20/20–20/25 0.89 (0.82–0.96)
20/40 to >20/80 20/30–20/50 0.81 (0.73–0.89)
20/80 to >20/200 20/60–20/100 0.57 (0.47–0.67)
20/200 to >20/400 20/200–20/400 0.52 (0.38–0.66)
20/400 Counting ﬁngers to
light perception
0.40 (0.29–0.50)
*Numbers in parentheses represent 95% conﬁdence intervals.
NA, not applicable; NV-AMD, neovascular age-related macular degeneration.
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Speciﬁcally, average annual noneye-related care costs
were extracted from Javitt et al. [18] by vision acuity
(Table 5). These costs were then inﬂated to 2006
dollars using the medical consumer price index [35].
Costs and odds ratios are presented in Table 6. The
model assumed that the cost of nursing home care was
independent of visual acuity; the average cost of a
semiprivate nursing home room in the United States
was included in the model [36]. The model also
accounted for resource use and costs for low-vision
rehabilitation and vision aids; inputs were based on
interviews with clinical experts.
Transition Probabilities
Transitions between visual acuity levels were based on
a3-line gain, no progression (deﬁned as <3-line loss),
a 3- to 6-line loss, and a 6-line loss on the visual
acuity scale as seen in the V.I.S.I.O.N. trial [15,24,25].
Speciﬁcally, 3-month transition probabilities for the
ﬁrst and second years were estimated from clinical
efﬁcacy results of years 1 and 2 (Table 1). In year 3 and
beyond after treatment is discontinued, patients in
both the pegaptanib and usual care cohorts were
assumed to progress through the model according to
transition probabilities as estimated for year 2 in the
usual care cohort. As some efﬁcacy may be thought to
remain after treatment discontinuation, sensitivity
analysis was performed to examine the impact of
improved efﬁcacy over usual care in year 3 and
beyond. Transitioning between health states was
adjusted to be applicable among patients who did not
die in each 3-month period. Efﬁcacy by lesion subtype
also was considered within the model. Nevertheless,
because pegaptanib was shown to be equally efﬁca-
cious in all lesion subtypes, transitioning between
visual acuity health states was similar for all lesion
subtypes [15,24].
Model Outcomes
To evaluate the clinical and economic beneﬁts of treat-
ing patients earlier in the disease state, lifetime vision-
years, QALYs, lifetime total costs per patient, and
incremental costs per vision-year and QALYs gained
are reported for pegaptanib and usual care stratiﬁed by
disease severity (early, moderate, and late subfoveal
NV-AMD). Costs are reported in 2006 US dollars.
Costs and outcomes were discounted at 3% per
annum.
Sensitivity Analyses
Several one-way sensitivity analyses were performed
to test the impact of various assumptions in the
model on the robustness of the results. The following
parameters were varied in the sensitivity analyses:
cost and utility values for each model state; clinical
efﬁcacy after 1 and 2 years of treatment; probability
of adverse events; risk of death due to blindness; and
rate of treatment efﬁcacy after 2 years. Clinical efﬁ-
cacy was changed by varying the primary clinical end
point (not losing more than 15 letters) by 30%. All
transition probabilities were changed proportionately.
Utility values were at the lower 95% conﬁdence limit
(lower bound) and at the upper 95% conﬁdence limit
(upper bound).
Table 3 Resource use and cost parameters for primary and concomitant therapies
Primary therapy
Pegaptanib with PDT Usual care with PDT
Year 1 Year 2 Year 1 Year 2
Treatments/year 1.71 1.00 2.05 1.54
% of patients receiving PDT 17.00 6.77 20.59 8.82
Concomitant therapy ($)
Drug cost 389.71 90.81 567.35 182.54
Procedure cost 161.71 46.29 235.42 93.05
Total concomitant therapy cost 551.42 137.10 802.77 275.59
Primary therapy ($)
Drug cost 8,859.48 7,277.43 4,562.46 2,952.18
Procedure cost 2,250.66 1,848.75 1,893.21 1,504.83
Total primary therapy cost 11,110.14 9,126.18 6,455.67 4,457.01
PDT, photodynamic therapy with verteporﬁn.
Table 4 Adverse event treatment patterns and costs
Adverse event
Annual rate of
occurrence (%)
% of patients
treated Treatment pattern
Cost to treat
adverse event [34]
Endophthalmitis 1.35 100.00 Five outpatient appointments, vitreous tap
with injection and antibiotics
$1060.73
Traumatic injury to lens 0.56 100.00 Four outpatient appointments, cataract surgery $848.89
Retinal detachment 0.67 90.00 Four outpatient appointments, vitrectomy $1079.31
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Results
Gains with pegaptanib were seen in all three patient
cohorts but were most pronounced in patients receiv-
ing early care. Early treatment with pegaptanib
provided substantial gains in both vision-years and
QALYs (Table 7). The largest gains in vision-years and
QALYs occurred in early subfoveal NV-AMD patients
treated with pegaptanib (Fig. 2). For example, com-
pared with usual care, patients with early disease
treated with pegaptanib gained 0.75 more vision-years
and 0.32 more QALYs compared to 0.22 more vision-
years and 0.09 more QALYs, respectively, for patients
with more severe vision. In addition to the clinical
beneﬁt to patients, an economic beneﬁt for payers was
observed. On average, patients treated early with
either pegaptanib or usual care incurred lower lifetime
total direct costs than those treated later (Table 7). For
pegaptanib-treated patients, total treatment costs for
early NV-AMD patients averaged $66,638 compared
to $96,771 for those with late NV-AMD; parallel costs
for patients receiving usual care were $55,108 and
$84,400, respectively. Although patients on pegap-
tanib had larger drug costs (>$11,000 for each pegap-
tanib treatment group vs. <$700 for each usual care
group), these costs accounted for only 11% to 23% of
the total costs. The greatest cost offsets occurred in the
category of other medical costs (i.e., costs of treating
other comorbidities). The largest differential in other
medical costs was in the early NV-AMD group, where
such costs were $6181 lower in those treated with
pegaptanib versus usual care. Incremental costs per
vision-year gained and per QALY gained for early
subfoveal NV-AMD patients were approximately one-
third those of patients with late disease ($15,279 vs.
$57,230 and $36,282 vs. $132,381, respectively;
Fig. 3).
Sensitivity Analysis
Sensitivity analysis showed that base-case incremental
costs per QALY gained for pegaptanib versus usual
care were relatively robust to changes in all parameters
examined in patients with early and moderate sub-
Table 5 Relative risk of comorbidities and associated resource utilization
Relative risk due
to visual acuity
Average annual cost/patient
associated with resource ($)
Total annual medical cost/patient
associated with resource ($)
Model state: 20/40 to >20/80
Depression-related medical care 1.42 3,450.17 629.83
Bone fracture medical care 1.27 6,372.06 671.51
Skilled nursing facility stays 1.48 5,529.41 600.53
Nursing home stays 1.45 61,685.00 4,462.84
Model state: 20/80 to >20/200
Depression-related medical care 1.49 4,580.12 877.31
Bone fracture medical care 1.35 6,649.37 744.87
Skilled nursing facility stays 1.81 5,894.16 782.87
Nursing home stays 1.77 61,685.00 5,447.75
Model state: 20/200 to >20/400
Depression-related medical care 1.84 4,207.75 995.31
Bone fracture medical care 1.34 8,213.42 913.26
Skilled nursing facility stays 2.84 5,429.64 1,131.57
Nursing home stays 2.62 61,685.00 8,063.89
Table 6 Odds ratios and annual cost associated with resource use due to vision loss
Depression
medical care
Bone fracture
medical care
Skilled nursing
facility stays
Nursing home
stays
% of patients with normal
vision using resource
12.86 8.30 7.34 4.99
Odds ratios by visual acuity
in the better-seeing eye
>20/40 1.00 1.00 1.00 1.00
20/40 to >20/80 1.42 1.27 1.48 1.45
20/80 to >20/200 1.49 1.35 1.81 1.77
20/200 to >20/400 1.84 1.34 2.84 2.62
20/400 1.84 1.34 2.84 2.62
Annual cost by visual acuity
in the better-seeing eye ($)
>20/40 Reference state Reference state
20/40 to >20/80 2487.52 1278.35
20/80 to >20/200 3744.32 3357.52
20/200 to >20/400 5039.69 9076.65
20/400 5039.69 9076.65
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foveal NV-AMD (Figs. 4 and 5). In these patients,
results were sensitive to changes in clinical efﬁcacy
both at 1 and 2 years and in patient utility of more
severe vision health states. Changes in clinical efﬁcacy
in year 1 only resulted in being the second most sen-
sitive parameter in patients with early disease. Never-
theless, changes in results were not that variable. In
patients with late disease, similar sensitivity in param-
eters occurred (Fig. 6). Nevertheless, changes in clini-
cal efﬁcacy at both 1 and 2 years and patient utility
and costs of more severe vision health states seemed to
have a larger impact on the incremental cost per QALY
gained. The model was not sensitive to ranges of com-
bined probabilities of adverse events, costs, and utili-
ties in less severe vision health states, and discount
rates normally accepted in cost-effectiveness models
(data not shown).
In addition to the above sensitivity analyses, we ran
a worst-case scenario under which pegaptanib may
perform. In this analysis, pegaptanib clinical beneﬁt at
both years 1 and 2 was decreased by 30%, no clinical
beneﬁt in years 3+ occurred, and the probability of
pegaptanib-related adverse events was increased by
30%. For patients with early, moderate, and late
NV-AMD, the incremental cost per QALY was
$82,996, $96,122, and $185,415, respectively.
Discussion
Previous research conducted in the United States has
demonstrated that pegaptanib is more cost-effective
overall than either no treatment [37] or treatment with
PDT and verteporﬁn [38]. Results of the current study
suggest that early treatment with pegaptanib offers
both direct medical beneﬁt to patients and economic
beneﬁt to payers. Early treatment improves cost-
effectiveness of care compared to waiting until visual
acuity worsens. Our study suggests that early treat-
ment also reduces lifetime total direct costs of care.
Incremental cost-effectiveness ratios for pegaptanib
compared to usual care are more favorable throughout
all three stages of subfoveal NV-AMD, but the greatest
incremental beneﬁts were seen in those treated early.
The actual cost-effectiveness of early pegaptanib
treatment may be more attractive than reﬂected by the
model because pegaptanib’s broad indication and
mechanism of action may reduce the complexity of the
clinical treatment pathway. For example, the decision
to re-treat with pegaptanib every 6 weeks is not predi-
cated on ﬁndings of ﬂuorescein angiography. There-
fore, personnel time and costs associated with such
diagnostic testing may be avoided. In addition, patient
ﬂow may be facilitated by the fact that those receiving
pegaptanib do not require lengthy post-treatment
observation in the clinician’s ofﬁce.
Table 7 Lifetime vision-years, QALYs, and total treatment cost per patient
Treatment start
Early NV-AMD Moderate NV-AMD Late NV-AMD
Pegaptanib Usual care Pegaptanib Usual care Pegaptanib Usual care
Vision-years 5.26 4.50 3.75 3.12 0.42 0.21
QALYs 4.75 4.44 3.59 3.38 2.86 2.77
Drug cost ($) 14,826 668 13,640 573 11,147 472
Administration cost ($) 3,845 291 3,538 249 2,893 204
Other medical cost ($) 47,968 54,149 67,007 70,571 82,732 83,725
Total treatment cost ($) 66,638 55,108 84,185 71,393 96,771 84,400
NV-AMD, neovascular age-related macular degeneration; QALY, quality-adjusted life-year.
0.75
0.32
0.63
0.220.22
0.09
0
0.20
0.40
0.60
0.80
1.00
Vision-Years Gained                           QALYs Gained
Y
ea
rs
Early
Moderate
Late
NV-AMD Stage at Treatment:
Figure 2 Lifetime vision-years and quality-adjusted life-years (QALYs)
gained: pegaptanib versus usual care. NV-AMD, neovascular age-related
macular degeneration.
15,279
36,282
20,350
58,28057,230
132,381
$-0
$25,000
$50,000
$75,000
$100,000
$125,000
$150,000
Incremental Cost per Vision-
Year Gained
Incremental Cost per QALY
Gained
U
S
$/
U
ni
t
Early
Moderate
Late
NV-AMD Stage at Treatment:
Figure 3 Incremental cost per vision-year and quality-adjusted life-year
(QALY) gained: pegaptanib versus usual care. NV-AMD, neovascular age-
related macular degeneration.
Early and Late NV-AMD Treatment with Pegaptanib 569
The cost-effectiveness of early treatment with
pegaptanib parallels ﬁndings of a subanalysis of
V.I.S.I.O.N. trial [16] data that explored visual acuity
outcomes in patients with early disease. In general,
pegaptanib treatment of patients with early NV-AMD
resulted in superior vision-related outcomes compared
to outcomes for the overall population of pegaptanib-
treated patients. Moreover, pegaptanib treatment
was associated with better outcomes than usual care
among patients with early disease. Thus, responder
rates (loss of <15 letters of visual acuity) were signiﬁ-
cantly higher among pegaptanib-treated patients while
those receiving usual care lost signiﬁcantly more letters
and were more likely to have severe vision loss than
patients treated with pegaptanib [16].
One would ideally like to compare our ﬁndings to
those of previous economic analyses [14,39–41]. Nev-
ertheless, such comparison is hindered by heterogene-
ity with regard to lesion types studied, model time
horizons, health states analyzed, vision loss-related
costs included, and use of the better or worse eye or
both. Although lifetime model time horizons are rec-
ommended to ensure that long-term health and cost
beneﬁts of treatment are captured [42], the only eco-
nomic analysis of PDT to use a lifetime model was
conducted by Sharma et al. [14]. Their Markov model
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utilized 12- and 24-month efﬁcacy data to estimate
the cost-effectiveness of PDT over the remaining life
expectancy of patients. The cost per QALY gained for
AMD patients whose better-seeing eye had only minor
vision loss at baseline (visual acuity: 20/40) was
$43,547. In patients whose treated eye had more
severe vision loss (20/200), the cost per QALY gained
was $87,196.
A recent economic model by Bandello et al. [43]
has attempted to estimate the impact of three treat-
ment interventions––verteporﬁn, pegaptanib, and
anecortave––on vision, comorbdities (depression and
bone fracture), institutionalization, and mortality,
using a simulation of the natural history of AMD
disease progression. Their model uses a starting visual
acuity of 0.7 logMar (20/100) in the worse eye and
calculates the risk of AMD in the second eye, progres-
sion to blindness in both eyes (deﬁned as 20/200 or
worse) and mortality. Although the model proposed by
Bandello et al. [43] offers seven starting states of visual
acuity, these are very broadly deﬁned (e.g., “ﬁrst eye
affected and second spared”), could overlap, and do not
offer very practical guidance to ophthalmologist who
deal with much more precise deﬁnitions of vision.
Treatment outcomes are not reported in cost-
effectiveness units, and it is thus difﬁcult to compare
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Bandello’s model with the one offered here. In addition,
the data used to populate Bandello’smodel are based on
1-year efﬁcacy data for the three comparators, while we
utilize 2 years of clinical efﬁcacy data to extrapolate
more precisely the lifetime impact of treatment.
Our study differs in two important respects from
prior reports. Unlike previous models, our model fully
considered the entire spectrum of NV-AMD subtypes,
all direct costs, and the natural progression of the
disease over a lifetime. The model thus provides more
accurate estimates of the cost-effectiveness of AMD
treatments than previous models. Second, the struc-
ture, assumptions, and input parameters of the model
were validated by an outside panel of clinical experts.
Like all modeling exercises, our study has several
limitations. First, we were not able to include indirect
costs for missed work and caregiver burden because of
lack of data. Including such parameters and taking a
US societal rather than a US payer perspective would
certainly lead to more favorable incremental cost-
effectiveness ratios for pegaptanib versus usual care
because patients receiving pegaptanib would likely
miss fewer days of work and require less assistance
with activities of daily living than those receiving usual
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care. Second, utility decrements were not assigned to
adverse events because no reliable source of such
decrements could be found. Nevertheless, the known
adverse events experienced by patients receiving
pegaptanib were both mild and infrequent. It is not
likely that the results would be substantially affected if
utility decrements for adverse events were included. A
model developed by Brown et al. [40] did include
utility decrements for adverse events and the total
effect was only 0.002 QALYs. Third, although the
model used pegaptanib as the sole comparator to usual
care, two other VEGF inhibitors, ranibizumab and
bevacizumab, also are being used to treat NV-AMD;
future models should assess the cost-effectiveness of
these therapies as well. Fourth, utility estimates were
based on vision in the better-seeing eye; it would be
useful, but considerably more complex, to consider
bilateral visual acuity. Finally, after year 2, model efﬁ-
cacy rates were based on usual care rather than assum-
ing an ongoing beneﬁt of pegaptanib, a deliberately
pessimistic assumption that may underestimate the
true potential treatment beneﬁts of pegaptanib.
In conclusion, our study suggests that early treat-
ment with pegaptanib to optimize clinical outcomes is
more cost-effective from a US payer perspective than
waiting for the onset of advanced or late disease. For
patients with subfoveal NV-AMD, treatment with
pegaptanib should be started as early as possible to
maximize the clinical and economic beneﬁts.
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